Global Wellness Pharma Subsidiary Supports Cancer Therapeutic Company AVM Biotechnology

 Vancouver, British Columbia, December 05, 2022 – Global Wellness Strategies Inc. (CSE: GWS) (Frankfurt: O3X4) (OTCQB: GWSFF) (“Global Wellness” or the “Company”) pharma subsidiary is excited to work with BioMed360 a GWS medical advisor. 

GWS pharma subsidiary is focused on providing companies with financial, operational, and management assistance during their clinical trials phase. GWS announces that BioMed360 Solutions Corp signed a letter of intent for the 100% acquisition of AVM Biotechnology. AVM Biotechnology is developing and advancing a proprietary formulation of its unique molecule AVM0703. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta+ Natural Killer T-like (AVM-NKT) immune cells. These AVM-NKT cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and early clinical data indicate that these cells could play a significant role in several diseases and conditions. 

“Immunotherapy causes fewer side effects than other treatments, because it targets just your immune system and not all the cells in your body. Immunotherapies help to slow, stop and kill cancerous cells, and for some patients can be safer and more effective than even chemotherapy and radiation. Our mission at Global Wellness has always been to embrace health and wellness, and we look forward to assisting BioMed 360 and AVM Biotechnology with their clinical trials capital needs.” said Meris Kott, CEO Global Wellness Strategies Inc. 

About Global Wellness Strategies: 

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies. 

For further information visit websites: 

Or Contact Meris Kott CEO 604.484.0355 or email to [email protected] 

Further information about the Company is available on under the Company’s profile. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.